Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
09/03/2022 14:21
March 9 (Reuters) - Enzychem Lifesciences Corp 183490.KQ :
* ENZYCHEM LIFESCIENCES ANNOUNCES COMPLETION OF CLINICAL
STUDY
REPORT (CSR) FOR PHASE 2 STUDY OF EC-18 IN
CHEMORADIATION-INDUCED ORAL MUCOSITIS
Source text for Eikon: ID:nBw9GBYrLa
Further company coverage: 183490.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enzychem Lifesciences
See all newsBrief: Enzychem Lifesciences To Divest 8 Billion Won Worth Of Own Shares
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot